| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 11 | 2022 | 2979 | 1.150 |
Why?
|
| Mutation | 29 | 2023 | 15179 | 0.960 |
Why?
|
| Myeloproliferative Disorders | 6 | 2022 | 767 | 0.950 |
Why?
|
| Polymerase Chain Reaction | 5 | 2016 | 3203 | 0.840 |
Why?
|
| Leukemia, Erythroblastic, Acute | 5 | 2018 | 118 | 0.820 |
Why?
|
| Leukemia, Myeloid, Acute | 15 | 2023 | 6915 | 0.780 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 6 | 2018 | 801 | 0.720 |
Why?
|
| Nuclear Proteins | 10 | 2022 | 3343 | 0.680 |
Why?
|
| Nucleic Acid Denaturation | 2 | 2016 | 34 | 0.650 |
Why?
|
| MicroRNAs | 5 | 2018 | 2947 | 0.630 |
Why?
|
| Erythroid Cells | 3 | 2018 | 49 | 0.620 |
Why?
|
| Genetic Association Studies | 2 | 2019 | 1084 | 0.540 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2019 | 5539 | 0.500 |
Why?
|
| DNA Mutational Analysis | 8 | 2019 | 2283 | 0.500 |
Why?
|
| Temperature | 1 | 2016 | 506 | 0.490 |
Why?
|
| Inflammatory Breast Neoplasms | 2 | 2018 | 509 | 0.490 |
Why?
|
| ras Proteins | 5 | 2018 | 770 | 0.470 |
Why?
|
| Philadelphia Chromosome | 3 | 2016 | 793 | 0.460 |
Why?
|
| Aged, 80 and over | 36 | 2019 | 29902 | 0.460 |
Why?
|
| High-Throughput Nucleotide Sequencing | 8 | 2019 | 2291 | 0.460 |
Why?
|
| Erythroid Precursor Cells | 1 | 2012 | 61 | 0.430 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 305 | 0.420 |
Why?
|
| Electrophoresis, Capillary | 1 | 2011 | 31 | 0.410 |
Why?
|
| Uterine Cervical Diseases | 1 | 2011 | 25 | 0.400 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 3639 | 0.400 |
Why?
|
| Prognosis | 22 | 2023 | 21713 | 0.400 |
Why?
|
| Aged | 47 | 2021 | 70117 | 0.390 |
Why?
|
| Cytogenetic Analysis | 5 | 2014 | 568 | 0.390 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2022 | 2390 | 0.390 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2019 | 6207 | 0.380 |
Why?
|
| Body Mass Index | 1 | 2018 | 2203 | 0.370 |
Why?
|
| Immunophenotyping | 9 | 2022 | 1681 | 0.370 |
Why?
|
| Transition Temperature | 1 | 2009 | 8 | 0.360 |
Why?
|
| Point Mutation | 2 | 2012 | 769 | 0.360 |
Why?
|
| Cervix Uteri | 1 | 2011 | 253 | 0.350 |
Why?
|
| Hematologic Neoplasms | 3 | 2023 | 1870 | 0.350 |
Why?
|
| Adult | 43 | 2019 | 77950 | 0.350 |
Why?
|
| Middle Aged | 45 | 2019 | 86204 | 0.350 |
Why?
|
| Bone Marrow | 8 | 2018 | 2358 | 0.350 |
Why?
|
| Biomarkers, Tumor | 10 | 2018 | 10331 | 0.340 |
Why?
|
| Young Adult | 24 | 2018 | 21445 | 0.340 |
Why?
|
| Genetic Testing | 3 | 2019 | 1589 | 0.330 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2019 | 3552 | 0.310 |
Why?
|
| Placenta | 1 | 2011 | 516 | 0.300 |
Why?
|
| World Health Organization | 6 | 2018 | 316 | 0.290 |
Why?
|
| Humans | 70 | 2023 | 261506 | 0.290 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 526 | 0.280 |
Why?
|
| Gene Regulatory Networks | 1 | 2010 | 677 | 0.280 |
Why?
|
| Male | 46 | 2022 | 123000 | 0.270 |
Why?
|
| Female | 47 | 2022 | 141928 | 0.270 |
Why?
|
| Biomarkers | 4 | 2022 | 5047 | 0.270 |
Why?
|
| Computational Biology | 1 | 2012 | 1271 | 0.270 |
Why?
|
| GTP Phosphohydrolases | 2 | 2019 | 336 | 0.270 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2022 | 430 | 0.270 |
Why?
|
| Janus Kinase 2 | 3 | 2019 | 679 | 0.270 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2016 | 2488 | 0.260 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2015 | 489 | 0.260 |
Why?
|
| Precursor Cells, T-Lymphoid | 2 | 2022 | 23 | 0.260 |
Why?
|
| Gene Expression Profiling | 4 | 2016 | 5159 | 0.240 |
Why?
|
| Neoplasm Proteins | 4 | 2022 | 3230 | 0.240 |
Why?
|
| Receptor, Notch1 | 2 | 2022 | 218 | 0.230 |
Why?
|
| Papillomavirus Infections | 1 | 2011 | 980 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 810 | 0.220 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2023 | 1331 | 0.220 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 1046 | 0.210 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2022 | 118 | 0.210 |
Why?
|
| Populus | 1 | 2021 | 1 | 0.210 |
Why?
|
| Disease-Free Survival | 11 | 2022 | 10001 | 0.210 |
Why?
|
| Adolescent | 18 | 2019 | 31252 | 0.210 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2023 | 255 | 0.200 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2021 | 33 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 15862 | 0.190 |
Why?
|
| Lymphoma, Follicular | 2 | 2016 | 587 | 0.190 |
Why?
|
| Survival Rate | 10 | 2022 | 12221 | 0.180 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2019 | 12 | 0.180 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2019 | 13 | 0.180 |
Why?
|
| Disease Progression | 6 | 2018 | 6682 | 0.180 |
Why?
|
| Lichenoid Eruptions | 1 | 2019 | 36 | 0.170 |
Why?
|
| Chromosome Aberrations | 5 | 2018 | 1960 | 0.170 |
Why?
|
| In Situ Hybridization | 3 | 2016 | 1037 | 0.170 |
Why?
|
| Thrombocytosis | 1 | 2019 | 121 | 0.170 |
Why?
|
| Immunohistochemistry | 7 | 2021 | 7548 | 0.170 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2019 | 114 | 0.160 |
Why?
|
| Bone Marrow Cells | 3 | 2011 | 943 | 0.160 |
Why?
|
| B-Lymphocytes | 3 | 2021 | 1294 | 0.160 |
Why?
|
| Thinness | 1 | 2018 | 82 | 0.160 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2021 | 301 | 0.160 |
Why?
|
| Retrospective Studies | 15 | 2019 | 37905 | 0.150 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2018 | 115 | 0.150 |
Why?
|
| Genomics | 3 | 2019 | 2738 | 0.150 |
Why?
|
| Clonal Evolution | 1 | 2019 | 253 | 0.150 |
Why?
|
| Texas | 7 | 2014 | 6311 | 0.150 |
Why?
|
| Hodgkin Disease | 2 | 2018 | 1429 | 0.150 |
Why?
|
| Membrane Proteins | 2 | 2019 | 2819 | 0.150 |
Why?
|
| Drug Eruptions | 1 | 2019 | 256 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2016 | 2508 | 0.150 |
Why?
|
| Carrier Proteins | 2 | 2016 | 2022 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 2796 | 0.140 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 245 | 0.140 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2019 | 259 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2019 | 417 | 0.140 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2016 | 88 | 0.140 |
Why?
|
| DNA, Neoplasm | 2 | 2012 | 1910 | 0.140 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2017 | 1664 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2016 | 641 | 0.140 |
Why?
|
| Flow Cytometry | 4 | 2022 | 3033 | 0.130 |
Why?
|
| Genes, myc | 1 | 2017 | 358 | 0.130 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2016 | 52 | 0.130 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2018 | 1094 | 0.130 |
Why?
|
| Leukemia, B-Cell | 1 | 2016 | 117 | 0.130 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2016 | 160 | 0.130 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2018 | 2527 | 0.130 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2015 | 37 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2023 | 6550 | 0.130 |
Why?
|
| CD5 Antigens | 1 | 2015 | 112 | 0.120 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2014 | 68 | 0.120 |
Why?
|
| Overweight | 1 | 2018 | 484 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2018 | 2232 | 0.120 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2018 | 480 | 0.120 |
Why?
|
| Gene Dosage | 1 | 2017 | 829 | 0.120 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 4971 | 0.120 |
Why?
|
| Genes, abl | 2 | 2012 | 110 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2023 | 1283 | 0.120 |
Why?
|
| Skin | 1 | 2019 | 1259 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 2 | 2013 | 181 | 0.120 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2015 | 365 | 0.110 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2019 | 713 | 0.110 |
Why?
|
| Alleles | 1 | 2019 | 2437 | 0.110 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2016 | 261 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 3251 | 0.110 |
Why?
|
| Chromosome Disorders | 1 | 2015 | 417 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 8873 | 0.110 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2014 | 310 | 0.100 |
Why?
|
| Thioredoxins | 1 | 2012 | 50 | 0.100 |
Why?
|
| Neoplasms | 3 | 2019 | 15193 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2011 | 402 | 0.100 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 2138 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2012 | 9180 | 0.100 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 1323 | 0.100 |
Why?
|
| DNA Probes | 1 | 2011 | 217 | 0.100 |
Why?
|
| Karyotype | 2 | 2023 | 234 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 10035 | 0.090 |
Why?
|
| Ikaros Transcription Factor | 1 | 2010 | 54 | 0.090 |
Why?
|
| Nose Neoplasms | 1 | 2013 | 229 | 0.090 |
Why?
|
| Prevalence | 1 | 2018 | 3260 | 0.090 |
Why?
|
| Vaginal Smears | 1 | 2011 | 192 | 0.090 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 1656 | 0.090 |
Why?
|
| Classification | 1 | 2009 | 41 | 0.090 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2010 | 72 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2014 | 335 | 0.090 |
Why?
|
| Remission Induction | 4 | 2018 | 3569 | 0.090 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 218 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2014 | 607 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 1493 | 0.090 |
Why?
|
| Microdissection | 1 | 2009 | 86 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 862 | 0.090 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2015 | 755 | 0.090 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 4654 | 0.090 |
Why?
|
| Biopsy | 4 | 2018 | 3443 | 0.090 |
Why?
|
| Clusterin | 1 | 2009 | 28 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 1360 | 0.090 |
Why?
|
| Child | 10 | 2018 | 29154 | 0.090 |
Why?
|
| Cold Temperature | 1 | 2009 | 121 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2010 | 290 | 0.080 |
Why?
|
| DNA Primers | 1 | 2011 | 1399 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2011 | 479 | 0.080 |
Why?
|
| Recurrence | 4 | 2018 | 4758 | 0.080 |
Why?
|
| Translocation, Genetic | 2 | 2015 | 1245 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2018 | 1217 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2013 | 1385 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 1866 | 0.080 |
Why?
|
| Algorithms | 1 | 2019 | 3890 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2016 | 1664 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2010 | 1053 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 1216 | 0.080 |
Why?
|
| Pregnancy Outcome | 1 | 2011 | 643 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 3578 | 0.080 |
Why?
|
| Phenotype | 2 | 2016 | 6295 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 2013 | 904 | 0.080 |
Why?
|
| Time Factors | 4 | 2019 | 12926 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2018 | 2967 | 0.070 |
Why?
|
| ErbB Receptors | 1 | 2015 | 2295 | 0.070 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 482 | 0.070 |
Why?
|
| Primary Myelofibrosis | 1 | 2015 | 831 | 0.070 |
Why?
|
| Premature Birth | 1 | 2011 | 407 | 0.070 |
Why?
|
| Mycosis Fungoides | 1 | 2009 | 320 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 4821 | 0.070 |
Why?
|
| Obesity | 1 | 2018 | 2884 | 0.070 |
Why?
|
| Gene Deletion | 1 | 2010 | 1442 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 3869 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2019 | 6869 | 0.060 |
Why?
|
| Risk Factors | 4 | 2019 | 17523 | 0.060 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 7789 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 4053 | 0.060 |
Why?
|
| Lactate Dehydrogenases | 1 | 2023 | 7 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 2 | 2012 | 2330 | 0.060 |
Why?
|
| Piperidines | 2 | 2019 | 1035 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2021 | 32848 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2011 | 1350 | 0.060 |
Why?
|
| Karyotyping | 2 | 2017 | 1022 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2010 | 1756 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2015 | 9244 | 0.050 |
Why?
|
| Blast Crisis | 2 | 2018 | 557 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2013 | 7226 | 0.050 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 13658 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 14551 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 15694 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 2265 | 0.050 |
Why?
|
| Child, Preschool | 5 | 2018 | 16273 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 14889 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 4892 | 0.050 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2021 | 92 | 0.050 |
Why?
|
| Nitrogen | 1 | 2021 | 162 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2022 | 593 | 0.050 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 11538 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2021 | 148 | 0.050 |
Why?
|
| Awareness | 1 | 2021 | 126 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 6009 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2021 | 192 | 0.050 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2019 | 65 | 0.040 |
Why?
|
| Azetidines | 1 | 2019 | 87 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 826 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2023 | 1914 | 0.040 |
Why?
|
| Pregnancy | 1 | 2011 | 7573 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 5178 | 0.040 |
Why?
|
| Histiocytes | 1 | 2018 | 94 | 0.040 |
Why?
|
| Bone Marrow Examination | 1 | 2018 | 153 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2022 | 4744 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 275 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2021 | 4078 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2015 | 1450 | 0.040 |
Why?
|
| Arabinonucleosides | 1 | 2019 | 437 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2014 | 2450 | 0.040 |
Why?
|
| Codon | 1 | 2017 | 241 | 0.040 |
Why?
|
| Calcium | 1 | 2023 | 1537 | 0.040 |
Why?
|
| RNA Splicing Factors | 1 | 2017 | 153 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 4988 | 0.040 |
Why?
|
| Antigens, CD1 | 1 | 2016 | 49 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 2016 | 256 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2016 | 225 | 0.030 |
Why?
|
| Reticulin | 1 | 2015 | 22 | 0.030 |
Why?
|
| Core Binding Factors | 1 | 2016 | 112 | 0.030 |
Why?
|
| Vincristine | 1 | 2019 | 1511 | 0.030 |
Why?
|
| Adenine | 1 | 2018 | 631 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 644 | 0.030 |
Why?
|
| Dioxygenases | 1 | 2016 | 159 | 0.030 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2015 | 95 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2016 | 314 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2015 | 141 | 0.030 |
Why?
|
| Exons | 1 | 2018 | 1328 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 4757 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2019 | 1450 | 0.030 |
Why?
|
| Semiconductors | 1 | 2014 | 22 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2017 | 668 | 0.030 |
Why?
|
| Age Factors | 2 | 2015 | 5377 | 0.030 |
Why?
|
| Endoglin | 1 | 2013 | 43 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 2139 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 208 | 0.030 |
Why?
|
| Infant | 3 | 2016 | 13310 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2015 | 327 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2016 | 974 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 2292 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 324 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 3001 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2018 | 923 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2019 | 3005 | 0.030 |
Why?
|
| Abnormal Karyotype | 1 | 2012 | 100 | 0.030 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2011 | 58 | 0.030 |
Why?
|
| Fibrosis | 1 | 2015 | 793 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2019 | 929 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2017 | 1152 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 551 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1249 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 392 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 666 | 0.020 |
Why?
|
| Erythroblasts | 1 | 2010 | 24 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 1005 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2019 | 2086 | 0.020 |
Why?
|
| Sarcoma | 1 | 2021 | 1725 | 0.020 |
Why?
|
| Anemia, Refractory | 1 | 2010 | 39 | 0.020 |
Why?
|
| Cell Movement | 1 | 2018 | 2466 | 0.020 |
Why?
|
| Trisomy | 1 | 2011 | 231 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2013 | 671 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2018 | 1471 | 0.020 |
Why?
|
| Drug Design | 1 | 2012 | 375 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2018 | 1823 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 1946 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 14289 | 0.020 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2009 | 68 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 966 | 0.020 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2010 | 197 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2011 | 588 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2011 | 560 | 0.020 |
Why?
|
| Genes, ras | 1 | 2011 | 667 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 4975 | 0.020 |
Why?
|
| Genome, Human | 1 | 2016 | 1869 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 4298 | 0.020 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 461 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 2944 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2010 | 783 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2018 | 3518 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 2216 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 4109 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 4917 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 3045 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2010 | 1581 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 5437 | 0.020 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2009 | 387 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 7551 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 8865 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 7702 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2015 | 5270 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 2359 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2014 | 12873 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 34495 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 11965 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 59536 | 0.010 |
Why?
|